Insights from ARTEMIS-001

Author(s):

Panelists discuss how preliminary results from the pPhase 3 ARTEMIS-001 study indicate that iIfinatamab dDeruxtecan, a B7-H3 antibody-drug conjugate, demonstrates promising antitumor activity in relapsed small cell lung cancer, with a notable partial response rate and manageable safety profile among treated patients.

EP: 1.Current Landscape of First-Line Treatment for Limited-Stage SCLC: Diagnostic Workup & Multidisciplinary Approaches

EP: 2.Surgical and Radiotherapy Choices in Limited-Stage SCLC

EP: 3.Durvalumab in LS-SCLC: Exploring Phase 3 ADRIATIC Trial Outcomes and Implications

EP: 4.Immunotherapy in Limited-Stage SCLC

EP: 5.Defining Platinum Sensitivity in SCLC

EP: 6.Changing Standard of Care: Potential of Tarlatamab in SCLC Treatment

EP: 7.Adverse Event Management: CRS and ICANS with Tarlatamab

EP: 8.Tarlatamab in Combination Therapy: Future Potential for SCLC

EP: 9.Ifinatamab Deruxtecan and B7-H3 in SCLC

EP: 10.Comparing Treatment Schedules: Ifinatamab Deruxtecan vs Amrubicin, Topotecan, and Lurbinectedin in SCLC

Now Viewing

EP: 11.Insights from ARTEMIS-001

EP: 12.Targeted Therapies and Biomarkers for SCLC: What’s Next on the Horizon

Video content above is prompted by the following:

Dr Iams: Please provide your insights on outcomes from the ongoing Phase I ARTEMIS-001[study into which 11 of 53 (20.75%) patients with small cell lung cancer were enrolled.